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Introduction: This study compared survival after initial treatment 
with esophagectomy as primary therapy to induction therapy fol-
lowed by esophagectomy for patients with clinical T2N0 (cT2N0) 
esophageal cancer in the National Cancer Database (NCDB).
Methods: Predictors of therapy selection for patients with cT2N0 
esophageal cancer in the NCDB from 1998 to 2011 were identified 
with multivariable logistic regression. Survival was evaluated using 
Kaplan-Meier and Cox proportional hazards methods.
Results: Surgery was used in 42.9% (2057 of 4799) of cT2N0 patients. 
Of 1599 esophagectomy patients for whom treatment timing was 
recorded, induction therapy was used in 44.1% (688). Pretreatment 
staging was proven accurate in only 26.7% of patients (210 of 786) 
who underwent initial surgery without induction treatment and had 
complete pathologic data available: 41.6% (n = 327) were upstaged 
and 31.7% (n = 249) were downstaged. Adjuvant therapy (chemo-
therapy or radiation therapy) was given to 50.2% of patients treated 
initially with surgery who were found after resection to have nodal 
disease. There was no significant difference in long-term survival 
between strategies of primary surgery and induction therapy followed 
by surgery (median 41.1 versus 41.9 months, p = 0.51). In multivari-
able analysis, induction therapy was not independently associated 
with risk of death (hazard ratio [HR], 1.16, p = 0.32).
Conclusions: Current clinical staging for early-stage esophageal 
cancer is highly inaccurate, with only a quarter of surgically resected 
cT2N0 patients found to have had accurate pretreatment staging. 
Induction therapy for patients with cT2N0 esophageal cancer in the 
NCDB is not associated with improved survival.
Key Words: Esophageal cancer, Esophageal surgery, Induction ther-
apy, Outcomes
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The optimal management of patients with esophageal can-cer clinically staged as T2N0M0 (cT2N0) has not been 
definitively established.1 National Comprehensive Cancer 
Network guidelines for medically fit patients reflect the lack 
of definitive evidence and allow a wide spectrum of treat-
ment possibilities that include definitive chemoradiation and 
surgery with or without induction or adjuvant therapy, with 
some relatively minor differences between adenocarcinoma 
and squamous cell carcinoma histologies.2 Clinical staging 
modalities for this subset are known to be unreliable, with 
significant percentages of patients being understaged or over-
staged.3–7 Perhaps because clinical staging inaccuracies lead 
to a relatively high incidence of patients actually having nodal 
disease present at the time of surgical resection, induction 
therapy use in this setting has been increasing and was shown 
recently to exceed 50% for cases that were reported to the 
Society of Thoracic Surgeons General Thoracic Database in 
2011.3 However, induction therapy has not been definitively 
shown to improve outcomes in node-negative patients. The 
purpose of this study was to use one of the largest nationwide 
cancer databases to test the hypothesis that induction therapy 
followed by surgical resection is associated with improved 
survival compared with initial treatment with surgical resec-
tion for patients with cT2N0 esophageal cancer.
PATIENTS AND METHODS
The Duke University Institutional Review Board 
approved this retrospective review of patients diagnosed with 
cT2N0 esophageal cancer from 1998 to 2011 in the National 
Cancer Database (NCDB). The NCDB is maintained by the 
American College of Surgeons and the American Cancer 
Society and collects data from more than 1500 Commission 
on Cancer approved centers across the United States. The 
NCDB captures approximately 70% of all newly diagnosed 
cases of cancer annually and currently contains more than 30 
million patient records. Clinical stage is coded in the NCDB 
using the Facility Oncology Registry Data Standards and is 
defined as the clinical stage documented by the managing 
physician based on the best available information, but specific 
staging modality data are not available. The American Joint 
Committee on Cancer (AJCC) staging criteria for each patient 
are recorded in concordance with the year of diagnosis, and 
the AJCC fifth through seventh editions were therefore used 
to identify patients for inclusion in this study.8–10 As there 
were no changes in the definition of T2 or N0 disease across 
these editions, no attempts to re-code the clinical staging were 
necessary. Because the recommended treatment for cervical 
tumors is definitive chemoradiation, only patients with tumors 
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located in the middle- and distal-third of the esophagus were 
included for analysis. All survival analyses were limited to 
patients diagnosed through 2006, as long-term survival data 
are not currently available for patients diagnosed in 2007 or 
later in the NCDB
Patients were initially stratified based on the use of 
esophagectomy as part of their treatment (surgical manage-
ment versus nonoperative management). Independent predic-
tors of patients undergoing esophagectomy were then estimated 
using a logistic regression model that included patient age, 
sex, race, Charlson/Deyo comorbidity index, tumor histology 
(squamous cell versus adenocarcinoma), patient census tract 
education and income levels, patient travel distance to treat-
ment facility and facility type (academic versus community 
program). The primary analysis was then focused on patients 
who underwent surgical management with esophagectomy, 
with the primary predictor variable being the use of induc-
tion therapy versus an approach of surgery as the initial treat-
ment. For the purposes of this analysis, induction therapy was 
defined as the administration of any chemotherapy or radiation 
therapy (RT) before undergoing esophagectomy, and patients 
lacking data on the timing of therapy were excluded.
Baseline univariable comparisons of patient character-
istics and unadjusted outcomes between the cohort of patients 
who had surgery as the initial treatment and the cohort of 
patients who had induction therapy before esophagectomy 
were made using Student’s t test for continuous variables and 
Pearson’s χ2 test for categorical variables. To estimate the 
accuracy of clinical staging among the cT2N0 patient pop-
ulation, pathologic staging data were then used to calculate 
the respective rates of T- and N- upstaging and downstaging 
across the two groups after resection. To investigate the impact 
of pathologic N stage on use of adjuvant therapy, rates of post-
operative chemotherapy and RT were assessed, stratified by 
both the initial treatment approach (surgery versus induction) 
and pathologic nodal status. Unadjusted survival analyses 
were performed using the Kaplan-Meier method comparing 
survival curves with the log-rank test. All analyses evaluated 
overall survival, defined as time from date of diagnosis to date 
of death or censoring. Predictors of long-term survival for 
patients who had esophagectomy were estimated using a mul-
tivariable Cox proportional hazards model that included age, 
sex, race, Charlson/Deyo comorbidity index, final pathologic 
stage, tumor histology (squamous versus adenocarcinoma), 
patient census tract education and income levels, treatment 
facility volume and use of induction therapy.
Type I error was controlled at the level of the compari-
son, and a p value of less than 0.05 was considered statistically 
significant. Data are presented as median (interquartile range), 
counts (%), odds ratios or hazard ratios (95% confidence 
intervals [CI]) where applicable. All analyses were performed 
using R version 3.0.2, Vienna, Austria.
RESULTS
Of 93,164 patients with mid- or lower-third esophageal 
cancer in the database, 4799 patients were identified as cT2N0 
adenocarcinoma or squamous cell carcinoma with known treat-
ment characteristics (Fig. 1). Among these cT2N0 patients, 2057 
(42.9%) underwent esophagectomy as part of their treatment, 
and 2742 (57.1%) were treated with nonoperative management. 
Of the nonoperatively managed patients, 1864 (68.0%) received 
chemoradiation, 407 (14.9%) received RT alone, 83 (3.0%) 
received chemotherapy alone, and 376 (13.8%) received no 
definitive therapy. Living in a census tract with higher median 
education (adjusted odds ratio [AOR] 1.30, p = 0.013) and 
treatment at an academic medical center (AOR 2.61, p < 0.001) 
were independent predictors of undergoing esophagectomy 
among cT2N0 patients, whereas increasing patient age (AOR 
0.50, p < 0.001), female sex (AOR 0.64, p < 0.001), and squa-
mous cell histology (AOR 0.40, p < 0.001), were associated 
FIGURE 1.  Nationwide manage-
ment trends in cT2N0 esophageal 
cancer, 1998–2011.
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with nonoperative management. On unadjusted comparison 
of surgery to nonsurgical management, patients treated with 
esophagectomy had markedly better 5-year survival compared 
with their nonoperative counterparts who received combined 
chemoradiation therapy (39.2% [95% CI: 36.4–42.2%] versus 
16.6% [95% CI: 14.7–18.9%], p < 0.001).
After excluding the 498 (24.2%) esophagectomy 
patients who were missing complete data regarding the spe-
cific timing of chemotherapy and RT, 688 (44.1%) patients 
were treated with induction therapy, whereas the remaining 
871 (55.9%) were managed with surgery as their initial treat-
ment. Among the 688 patients who were given induction 
treatment, 605 (87.9%) were treated with chemoradiation, 15 
(2.2%) were treated with chemotherapy alone, and 68 (9.9%) 
were treated with RT alone. Comparison of the surgery-first 
versus induction therapy groups revealed fairly similar patient 
cohorts, although the induction therapy patients were younger, 
had lower Charlson comorbidity scores, more often had pri-
vate insurance, and had a higher proportion of tumors mea-
suring 5 cm or greater (Table 1). As also shown in Table 1, 
patients treated with induction therapy had a longer interval 
from diagnosis to surgery, had fewer lymph nodes retrieved, 
and were less likely to have positive margins after resection. 
There were no statistically significant differences between the 
two treatment approaches with respect to perioperative out-
comes, including 30-day mortality, unplanned readmissions 
within 30 days, or hospital length of stay.
Table 2 summarizes the pathological tumor stage data 
for both treatment groups. Among patients who had surgery 
as the initial treatment and had pathologic tumor, node, metas-
tasis staging data available (n = 786), only 210 (26.7%) were 
found to have had accurate pretreatment staging; 41.6% (327 
patients) were upstaged based on either pathologic T or N 
stage and 31.7% (249 patients) were downstaged. Although 
the true pretreatment pathologic stage is not known for the 
patients who were given induction therapy, the induction 
treatment patients had somewhat lower rates of upstaging and 
higher rates of downstaging. Although patients treated with 
induction therapy had slightly higher rates of stage 0 disease 
(5.9% versus 0.1%), comparison between groups revealed a 
highly similar distribution of overall pathologic stage. Patients 
receiving induction therapy had slightly lower rates of nodal 
upstaging, with 30.2% of the surgery-first group and 23.6% of 
the induction therapy group being pathologically node posi-
tive (p = 0.01). Of 109 patients with microscopic or macro-
scopic positive margins after resection, 72.4% were upstaged 
to pT3 or pT4; 76.6% of the surgery-first group with positive 
margins was upstaged, whereas 64.5% of induction therapy 
group was upstaged (p = 0.28).
Table 3 shows the use of adjuvant treatment after sur-
gery for patients who had not been given induction treatment. 
Overall, 22.8% (179 of 786) of patients who were treated 
with initial surgery and had data available regarding adjuvant 
treatment were subsequently given some form of adjuvant 
therapy (either chemotherapy, RT, or both). Patients who were 
upstaged because of having positive nodal disease were much 
more likely to receive adjuvant therapy than patients who had 
pathologic node-negative disease (50.2% [119 of 237] versus 
10.9% [60 of 549], p < 0.001). Of patients treated with surgery 
first who were subsequently upstaged because of node-posi-
tive disease, 15.6% (37 of 237) went on to receive adjuvant 
chemotherapy alone, 5.1% (12 of 237) were given adjuvant 
RT alone, and 29.5% (70 of 237) were given combined adju-
vant chemoradiation.
TABLE 1.  Baseline Characteristics and Outcomes Among 
Patients Treated with Esophagectomy, Stratified by Treatment 
Approach
Variable
Surgery First 
(n = 871)
Induction  
Therapy  
(n = 688) p Value
Patient characteristics
Age, yrs (interquartile 
range)
66 (58–73) 61 (54–68) <0.001
Female 152 (17.5%) 148 (14.2%) 0.061
Race 0.892
  White 800 (92.9%) 956 (92.7%)
  Black 46 (5.3%) 59 (5.7%)
  Other 15 (1.7%) 16 (1.6%)
Charlson Comorbidity 
Score
0.001
  0 489 (68.4%) 540 (77%)
  1 174 (24.3%) 127 (18.1%)
  ≥2 52 (7.3%) 34 (4.9%)
Census tract education 
above median
527 (63.7%) 610 (61.7%) 0.412
Census tract income above 
median
571 (69%) 661 (66.9%) 0.356
Insurance < 0.001
  Private 339 (40.2%) 576 (56.6%)
  Medicare 451 (53.5%) 366 (36%)
  Medicaid  33 (3.9%)  47 (4.6%)
  Government  7 (0.8%)  9 (0.9%)
  Uninsured  13 (1.5%)  20 (2%)
Tumor size < 0.001
  <1 cm  49 (6.3%)  49 (7.8%)
  1–1.9 cm 110 (14.1%)  46 (7.3%)
  2–4.9 cm 475 (61.1%) 337 (53.8%)
  >4.9 cm 144 (18.5%) 194 (31%)
Facility volume (cases/yr) 12 (6, 24) 8 (5, 17) < 0.001
Days to definitive surgery 
(interquartile range)
43 (29, 64) 131 (112, 157) < 0.001
Outcomes and endpoints
Nodes removed 
(interquartile range)
12 (6, 19) 7 (2, 13) < 0.001
Surgical margins 0.001
  Negative 763 (91.1%) 922 (95.5%)
  Positive margin 
-microscopic
 54 (6.4%)  29 (3%)
  Positive margin 
-macroscopic
 21 (2.5%)  14 (1.5%)
30-day mortality 37 (4.2%) 36 (3.5%) 0.437
30-day readmission 53 (7.6%) 37 (5.6%) 0.162
Hospital length of stay 
(interquartile range)
11 (8, 17) 10 (8, 15) 0.069
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There was no significant difference in long-term sur-
vival between an approach of surgery first (median survival 
41.1 months) versus induction therapy (median survival 
41.9 months, p = 0.51; Fig. 2A). Similarly, after stratifying 
patients treated with surgery into those who were node nega-
tive and those who were node positive, induction therapy was 
not associated with significantly different long-term survival 
in either case (p = 0.95 and p = 0.97 for node negative and 
positive, respectively; Fig. 2B, C). After Cox proportional 
hazards adjustment among patients treated with esophagec-
tomy, induction therapy was not found to be independently 
associated with risk of death (hazard ratio [HR] 1.16, 95% 
CI 0.87–1.56, p = 0.32). The only factors significantly associ-
ated with death were patient age (HR 1.22 per decade of life, 
p = 0.005), pathologic stage (HR 1.61 per stage group, p < 
0.001), and facility volume (HR 0.89 per 10 cases annually, 
p = 0.002; Table 4).
DISCUSSION
In this study, we found that management of patients 
in the NCDB with cT2N0 esophageal cancer included sur-
gery in the minority of patients, inconsistent with treatment 
guidelines.2 Treatment in the United States was rather variable, 
with 57% of patients being treated without surgery and slightly 
less than half of the patients who were treated operatively 
being first given induction therapy. However, patients whose 
management included esophagectomy had significantly better 
long-term survival than those treated nonoperatively. Factors 
associated with receiving esophagectomy included younger 
age, adenocarcinoma histology, demographic factors, and 
facility type. Clinical T and N status was found to be accurate 
in only 26.7% of patients, with 41.6% being pathologically 
upstaged and 31.7% being pathologically downstaged. Slightly 
more than half of node-positive surgery-first patients received 
adjuvant therapy. Induction therapy was used in nearly half of 
patients who underwent surgery, but was not associated with 
improved survival in multivariable analysis, even after stratify-
ing by pathologic nodal status. After adjustment, only younger 
patient age, higher facility volume, and lower pathologic stage 
were associated with improved long-term survival.
Previously published studies have shown conflicting 
results on the use of induction therapy for T2N0 esophageal 
cancer. Studies in support of induction therapy include a report 
of 49 patients from MD Anderson Cancer Center who had an 
excellent 10-year actuarial survival of greater than 60% associ-
ated with induction chemoradiation therapy followed by sur-
gical resection.1 In addition, the T2N0M0 esophageal cancer 
substage was included in a randomized trial that demonstrated 
a survival benefit to induction chemoradiotherapy followed by 
surgery compared with surgery alone for esophageal or esoph-
agogastric junction cancer.11 However, patients with T2N0M0 
disease represented a minority of the study participants; the 
number of clinical T2N0 patients included in this study was not 
specifically reported, but only 51 of 366 (17%) patients overall 
clinically had T2 disease with or without nodal disease.11 Other 
small studies have advocated for the use of induction therapy 
because of a high incidence of nodal disease detected after 
resection.6,7 However, analyses from at least two retrospective 
series have questioned whether induction therapy improves 
survival. In a study of the Surveillance, Epidemiology, and End 
Results database, patients treated with both RT and surgery, 
with RT being used before surgery in many cases, did not have 
improved survival compared with patients treated with surgery 
alone.12 In addition, another small single-center series found 
no survival advantage associated with induction therapy and 
advocated for initial treatment with surgery with adjuvant ther-
apy given if after resection the tumor was found to be initially 
understaged.5 The results of our present study support a treat-
ment strategy that does not routinely use induction therapy.
Interestingly, comparison of the survival curves for 
the two groups shows an apparent initial superior survival 
TABLE 3.  Utilization of Adjuvant Therapy, by Treatment Approach and Pathologic N Stage
Adjuvant Therapy Total (n = 786) Node Negative (n = 549) Node Positive (n = 237) p Value
Any therapy (either) 179 (22.8%) 60 (10.9%) 119 (50.2%) <0.001
Chemotherapy alone 61 (7.8%) 24 (4.4%) 37 (15.6%) <0.001
Radiation alone 23 (2.9%) 11 (2%) 12 (5.1%) 0.04
Chemoradiation 95 (12.1%) 25 (4.6%) 70 (29.5%) <0.001
TABLE 2.  Summary of Pathologic Tumor Stage Changes 
from Initial cT2N0, Among Patients with Pathologic Staging 
Data Available in National Cancer Database
Pathologic Staging
Surgery First 
(n = 786)
Induction  
therapy  
(n = 477) p Value
Accurate staging (pT2N0) 210 (26.7%) 116 (24.3%) 0.34
Upstaged (T or N) 327 (41.6%) 163 (34.2%) 0.01
Downstaged (T or N) 249 (31.7%) 198 (41.6%) <0.001
pT-stage <0.001
  T0/IS 6 (0.7%) 110 (22.5%)
  T1 243 (30.1%) 88 (18.0%)
  T2 334 (41.4%) 187 (38.2%)
  T3 210 (26.1%) 100 (20.4%)
  T4 13 (1.6%) 4 (0.8%)
pN-stage 0.013
  Node negative 549 (69.8%) 381 (76.4%)
  Node positive 237 (30.2%) 118 (23.6%)
Pathologic stage <0.001
  pStage 0 1 (0.1%) 23 (5.9%)
  pStage I 220 (28.4%) 95 (24.4%)
  pStage II 409 (52.8%) 209 (53.6%)
  pStage III 128 (16.5%) 58 (14.9%)
  pStage IV 16 (2.1%) 5 (1.3%)
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FIGURE 2. A, Kaplan-Meier survival estimates for cT2N0 patients undergoing esophagectomy, comparing induction therapy 
versus surgery first; 1998–2006. B, Kaplan-Meier survival estimates for cT2N0 patients found to be node negative after esopha-
gectomy, comparing induction therapy versus surgery first; 1998–2006. C, Kaplan-Meier survival estimates for cT2N0 patients 
found to be node positive after esophagectomy, comparing induction therapy versus surgery first; 1998–2006.
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followed by a delayed and sharp decrease among the induction 
therapy group in the first year after diagnosis. This finding is 
probably at least partially because of the timing of surgery in 
relation to the time of diagnosis in the two groups. Although 
the observed early survival difference may be partly related to 
the induction therapy itself, it is much more likely that this is 
the result of a treatment time-lag bias given that survival was 
assessed from date of diagnosis. Even though the two groups 
experienced similar rates of perioperative morbidity and mor-
tality, the induction therapy group had a substantially longer 
time interval between diagnosis and complications because of 
esophagectomy. The delay before surgery in the induction ther-
apy group is likely partially responsible for the early survival 
appearing to be better in this group compared with the patients 
that went straight to surgery early after their diagnosis.
Based on the rates of nodal upstaging and actual rates 
of adjuvant therapy delivery demonstrated in this study, 85% 
of surgery-first patients are treated according to National 
Comprehensive Cancer Network guidelines. On the other 
hand, while considering that 69.8% of cT2N0 patients are cor-
rectly staged as node negative, a strategy of induction therapy 
for cT2N0 disease may lead to administration of chemora-
diation that may not have been necessary in over two-thirds 
of cases. Although induction therapy has been shown to be 
safe and does not increase risk of surgery,3,13,14 overtreatment 
can lead to unnecessary morbidity and costs. In addition, our 
study may overestimate the benefits of induction therapy, 
because the initial treatment intent for the patients who were 
treated with chemotherapy and/or RT and did not get surgery 
is unknown. Some of those patients may have been started 
on chemotherapy or RT with the plan to ultimately undergo 
esophagectomy, but never made it to surgery. We are unable to 
identify instances of patient death after induction therapy but 
before definitive resection. However, previous studies have 
suggested that only a small number of patients do not proceed 
to resection, with disease progression the most common rea-
son that surgery is ultimately not utilized.15
Node-positive disease is a strong predictor of systemic 
disease and poor long-term survival.16,17 The benefit of induc-
tion therapy for patients who truly have N0 disease before 
therapy is likely to be minimal given their better prognosis and 
may needlessly subject these patients to the risks associated 
with chemotherapy and radiotherapy.5 However, in case of 
upstaging in the pathological report to node-positive disease, 
multimodality therapy could still be delivered using adjuvant 
radiotherapy and chemotherapy. This strategy is supported by 
others based on gastroesophageal adenocarcinomas.18 In our 
analysis of patients in the NCDB, over half of the node-pos-
itive surgery-first patients received some amount of adjuvant 
therapy. Although one potential downside of using esophagec-
tomy as the initial treatment is that morbidity or debilitation 
after surgery may prevent patients from receiving adjuvant 
chemotherapy, our analysis does not suggest that giving treat-
ment before surgery in this clinical setting ultimately improves 
survival. Interestingly, although the rates of nodal upstaging 
between patients who were given induction therapy and the 
patients who went straight to surgery were significantly differ-
ent statistically (23.6% versus 30.2%, p = 0.01), based on the 
observed survival in each group, this difference did not appear 
to be associated with improved survival.
The use of the NCDB has a significant strength of being 
able to investigate uncommon tumor stages with enough 
power to even perform subgroup analysis, due to its popu-
lation-based nature, especially considering that previously 
published reports on induction therapy for T2N0 esophageal 
cancer have been small and highly selected single-center 
experiences.1,5,6 Although a randomized trial would be ideal 
to definitively evaluate treatment strategies, such a trial is 
unlikely to ever happen considering the relative uncommon 
nature of this esophageal cancer substage. Even if such a 
trial were performed, it is extremely unlikely that any clinical 
trial will be able to assemble the number of patients that were 
considered in this study. However, clinicians should strongly 
consider including patients with this stage of disease in multi-
institutional registries to allow further evaluation of different 
treatment strategies and outcomes in a prospective fashion.
The NCDB does also have some inherent limitations. 
First, there is relatively limited information regarding patient 
comorbidities and functional status, which may be important 
in predicting both survival and treatment, particularly multi-
modality therapy. Even though multivariable adjusted analysis 
can correct for measured covariates, unmeasured confounding 
cannot be excluded. Additionally, specific details on chemo-
therapy agents and doses are not available. The NCDB also 
presents limitations in assessing overall stage, as patients are 
staged using the AJCC edition used at the time of diagnosis. 
Although this did not impact our primary analysis as the defi-
nition of clinical T2N0 did not change over time, this may 
have biased our results somewhat, particularly with respect to 
the inclusion of overall pathologic stage in the multivariable 
survival models. Also, details regarding the staging modalities 
used to establish the clinical T2N0 diagnosis for the patients 
TABLE 4.  Adjusted Predictors of Survival Among Patients 
Treated with Esophagectomy for cT2N0 Esophageal Cancer
Predictor
Hazard 
Ratio
Lower  
95% CI
Upper  
95% CI p Value
Induction therapy 1.16 0.87 1.56 0.32
Age (per decade) 1.22 1.06 1.40 0.005
Female sex 1.06 0.68 1.65 0.80
Race (ref = White)
 Black 1.13 0.52 2.48 0.76
 Other 1.14 0.39 3.34 0.81
Charlson/Deyo (0,1,2) 1.07 0.84 1.36 0.57
Squamous histology  
(vs. adenocarcinoma)
1.35 0.90 2.02 0.15
Pathologic Stage  
(per stage group)
1.61 1.33 1.94 <0.001
Education above  
median
1.05 0.73 1.50 0.80
Income above median 0.86 0.59 1.26 0.45
Facility volume  
(per 10 annual cases)
0.89 0.83 0.96 0.002
CI, confidence interval.
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in this study are not available. Modalities generally used to 
establish clinical esophageal cancer stage before treatment 
include computed tomography scanning, positron emission 
tomography (PET) scanning, endoscopic ultrasound (EUS), 
EUS with fine-needle aspiration, and laparoscopy. Similarly, 
it is likely that variability in staging modalities over the course 
of the study period may have led to different rates of stage 
migration over time, particularly as PET has become more 
accessible in recent years. EUS has also gained popularity and 
is a valuable tool in clinical staging, but is known to be less 
accurate for early-stage lesions such as T1 or T2 compared 
with more advanced tumors.5,19–21 Most incidences of under-
staging are because of missed nodal disease.4 As many as 55% 
of patients with clinically staged T2N0 esophageal cancers 
have previously been reported as having nodal disease after 
resection.5,6 The specificity and the sensitivity for identifying 
lymph node disease are better for EUS-fine-needle aspiration 
compared with EUS alone.22 If the use of staging modalities 
was not balanced between the groups, then the groups may 
have had different likelihoods of over- or understaging clini-
cally. However, the rates of under- and overstaging in this study 
are similar to previously published reports.3–7 Lastly, while we 
attempted to control for imbalance statistically, because of the 
retrospective nature of this study, there is potential for selec-
tion bias, particularly regarding the somewhat larger tumor 
size and smaller number of lymph nodes retrieved among the 
patients treated with induction therapy compared with their 
surgery-first counterparts.
In conclusion, treatment of cT2N0 esophageal cancer is 
variable. In the NCDB, less than half the patients had esopha-
gectomy as part of their treatment. For the patients that did 
have surgery, slightly less than half of patients had induction 
therapy before surgery. In this study, we did not find that induc-
tion therapy improved outcomes compared to surgery alone. 
We found that more than half of patients who had node-posi-
tive disease after esophagectomy without induction treatment 
received adjuvant therapy. The lack of benefit seen in this pop-
ulation-based analysis does not support the clinical practice of 
treating this stage of esophageal cancer with induction therapy, 
particularly when the cost and potential morbidity of induc-
tion therapy are considered. Although prospective studies in 
the form of either a randomized trial or through creation of a 
prospective registry would be ideal to more definitively estab-
lish optimal treatment, this current study suggests that the most 
efficient treatment strategy for cT2N0 esophageal cancer is 
initial surgery. Subsequent administration of adjuvant therapy 
can be considered for patients who are pathologically upstaged 
postoperatively; however, further study is necessary to deter-
mine whether this strategy improves survival.
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